ValuEngine upgraded shares of Ritter Pharmaceuticals (NASDAQ:RTTR) from a strong sell rating to a sell rating in a research note issued to investors on Friday.

Other research analysts have also recently issued research reports about the company. HC Wainwright reduced their target price on Ritter Pharmaceuticals from $7.00 to $1.50 and set a buy rating on the stock in a report on Monday, October 23rd. Zacks Investment Research cut Ritter Pharmaceuticals from a buy rating to a hold rating in a report on Tuesday, December 26th. Finally, Roth Capital set a $2.00 target price on Ritter Pharmaceuticals and gave the company a buy rating in a report on Monday, October 23rd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the stock. The company currently has a consensus rating of Hold and an average price target of $2.10.

Ritter Pharmaceuticals (RTTR) opened at $0.32 on Friday. Ritter Pharmaceuticals has a fifty-two week low of $0.28 and a fifty-two week high of $3.75.

An institutional investor recently bought a new position in Ritter Pharmaceuticals stock. Susquehanna International Group LLP acquired a new stake in Ritter Pharmaceuticals Inc (NASDAQ:RTTR) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 2,222,522 shares of the biotechnology company’s stock, valued at approximately $778,000. Susquehanna International Group LLP owned 4.49% of Ritter Pharmaceuticals at the end of the most recent reporting period. 33.38% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: This report was published by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another publication, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this report can be read at

Ritter Pharmaceuticals Company Profile

Ritter Pharmaceuticals, Inc develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Ritter Pharmaceuticals (NASDAQ:RTTR)

Receive News & Ratings for Ritter Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals and related companies with's FREE daily email newsletter.